Ilitch Aquino Marcondes-De-Castro

Ilitch Aquino Marcondes-De-Castro

Auto-generated profile, based on publicly available information

Ilitch Aquino Marcondes-De-Castro

Laboratory of Morphometry, Metabolism, and Cardiovascular disease, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2023 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
IMIlitch Aquino Marcondes‐De‐Castro
Ilitch Aquino Marcondes‐De‐Castro
PRPedro Henrique Reis‐Barbosa
Pedro Henrique Reis‐Barbosa
TMThatiany Souza Marinho
Thatiany Souza Marinho
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda

12 April 2022 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
PRPedro Henrique Reis-Barbosa
Pedro Henrique Reis-Barbosa
IMIlitch Aquino Marcondes-De-Castro
Ilitch Aquino Marcondes-De-Castro
TMThatiany de Souza Marinho
Thatiany de Souza Marinho
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda


8 February 2023 in Journal of Molecular Endocrinology
Verified
Journal Article
Closed access
PDF file
IMIlitch Aquino Marcondes-De-Castro
Ilitch Aquino Marcondes-De-Castro
TOThamiris Ferreira Oliveira
Thamiris Ferreira Oliveira
RSRenata Spezani
Renata Spezani
TMThatiany Souza Marinho
Thatiany Souza Marinho
LCLuiz Eduardo Macedo Cardoso
Luiz Eduardo Macedo Cardoso
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
Obesity, adipose tissue inflammation, and nonalcoholic fatty liver disease (NAFLD) are associated with insulin resistance and type 2 diabetes (T2D). Cotadutide is a dual agonist GLP-1/glucagon, currently in a preclinical study phase 2 that presents an anti-obesity effect. Diet-induced obese (DIO) C57BL/6 mice were treated for 4 weeks with cotadutide (30 nm/kg once a day at 14:00 h). The study focused on epididymal white adipose tissue (eWAT), liver (NAFLD), inflammation, lipid metabolism, AMP-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR) pathways, and the endoplasmic reticulum (ER) stress. As a result, cotadutide controlled weight gain, glucose intolerance, and insulin resistance and showed beneficial effects on plasma markers in DIO mice (triacylglycerol, total cholesterol, alanine aminotransferase, and aspartate aminotransferase, leptin, adiponectin, monocyte chemoattractant protein-1, resistin, interleukin-6, tumor necrosis factor-alpha). Also, cotadutide lessened liver fat accumulation, eWAT proinflammatory markers, and ER stress. In addition, cotadutide improved lipid metabolism genes in eWAT, fatty acid synthase, peroxisome proliferator-activated receptor gamma and mitigates adipocyte hypertrophy and apoptosis. Furthermore, the effects of cotadutide were related to liver AMPK/mTOR pathway and ER stress. In conclusion, cotadutide induces weight loss and treats glucose intolerance and insulin resistance in DIO mice. In addition, cotadutide shows beneficial effects on liver lipid metabolism, mitigating steatosis, inflammation, and ER stress. Besides, in adipocytes, cotadutide decreases hypertrophy and reduces apoptosis. These actions rescuing the AMPK and mTOR pathway, improving lipid metabolism, and lessening NAFLD, inflammation, and ER stress in both eWAT and liver of DIO mice indicate cotadutide as a potentially new pharmacological treatment for T2D and associated obesity.


16 December 2025 in Life Sciences
Verified
Journal Article
Closed access
JBJulie Oliveira A. Bittencourt
Julie Oliveira A. Bittencourt
IMIlitch A. Marcondes-De-Castro
Ilitch A. Marcondes-De-Castro
TMThatiany Souza Marinho
Thatiany Souza Marinho
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda